Tolsura
PreclinicalSmall molecule
Tolsura is one of 41 small molecule programs targeting Lung Transplantation. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
57 competitors in Lung Transplantation
#DrugCompanyPhaseTrials
1Neoral
NovartisApproved
Opsumit
Johnson & JohnsonApproved
Tavalisse
RRigel Pharmaceuticals
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Imuran
LLegacy Health System
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Cecon
MMcGuff Pharmaceuticals, Inc.
Approved
Rezurock
KKadmon, a Sanofi Company
Approved
Calcineurin Inhibitors
SanofiApproved
Afinitor
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tolsura. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHong Nguyen